CH-3-8

CH-3-8 is a novel small molecule tubulin polymerization inhibitor and microtubule destabilizer designed to overcome multidrug resistance in solid tumors, particularly pancreatic ductal adenocarcinoma (PDAC) and metastatic melanoma. It acts by binding to the colchicine binding site of tubulin, thereby inhibiting microtubule assembly and inducing cell cycle arrest and apoptosis. A key feature of CH-3-8 is its ability to bypass multidrug resistance proteins, specifically MRP7 (ABCC10), which often mediate resistance to traditional taxanes like paclitaxel. To enhance its therapeutic index and penetrate the dense stroma characteristic of pancreatic cancer, CH-3-8 is frequently developed as a lipid-drug conjugate (LDC) or encapsulated within pH-sensitive nanoparticles. Preclinical studies have demonstrated that systemic administration of these nanoformulations results in significant tumor regression and reduced systemic toxicity compared to free drug or conventional chemotherapy.